Omeros Corporation
Omeros is a biopharmaceutical company dedicated to pioneering innovative therapeutics through groundbreaking science. Their mission is to develop first-in-class drugs that address significant unmet medical needs, focusing on areas such as complement-mediated diseases, central nervous system disorders, and immuno-oncology. With a deep and diverse pipeline of small-molecule and protein therapeutics, Omeros aims to transform patient care by targeting previously untapped receptors and enzymes. The company emphasizes a culture of talented, passionate, and collaborative individuals committed to providing hope to patients worldwide.
Industries
Nr. of Employees
large (251-1000)
Omeros Corporation
The Omeros Building, 201 Elliott Avenue West, Seattle, WA 98119
Patents
Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome
US-12351648-B2
View DetailsMonoclonal antibodies, compositions and methods for detecting complement factor D
US-12129290-B2
View DetailsTherapeutic antibodies that bind to the serine protease domain of MASP-2 and uses thereof
US-12091468-B2
View Details
Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome
US-12351648-B2
View DetailsMonoclonal antibodies, compositions and methods for detecting complement factor D
US-12129290-B2
View DetailsTherapeutic antibodies that bind to the serine protease domain of MASP-2 and uses thereof
US-12091468-B2
View DetailsProducts
Monoclonal antibody targeting lectin-pathway protease (MASP-2 inhibitor)
Therapeutic monoclonal antibody designed to inhibit the lectin complement pathway effector protease to prevent complement-mediated inflammation and endothelial damage; advanced in clinical development for transplant-associated thrombotic microangiopathy and other indications.
Monoclonal antibody targeting alternative-pathway activator (MASP-3 inhibitor)
Antibody therapeutic designed to inhibit MASP-3 to block activation of the alternative complement pathway; in clinical development for paroxysmal nocturnal hemoglobinuria and other alternative-pathway disorders.
PDE7 small-molecule inhibitor for addiction disorders
Oral small-molecule phosphodiesterase 7 inhibitor developed to modulate dopamine pathways implicated in substance use disorders and reduce craving and relapse behaviors; progressed through Phase 1 clinical trials.
PPARγ small-molecule modulators for addiction
Small-molecule PPARγ agonists explored for reduction of craving and modulation of anxiety in substance use disorders; supported by investigator-led and NIH-funded clinical studies.
Targeted Complement Activation Therapeutics (T-CAT platform)
Engineered fusion-protein platform combining complement pathway effectors with antigen-targeting domains to direct complement-mediated killing of pathogens, including multidrug-resistant organisms.
Monoclonal antibody targeting lectin-pathway protease (MASP-2 inhibitor)
Therapeutic monoclonal antibody designed to inhibit the lectin complement pathway effector protease to prevent complement-mediated inflammation and endothelial damage; advanced in clinical development for transplant-associated thrombotic microangiopathy and other indications.
Monoclonal antibody targeting alternative-pathway activator (MASP-3 inhibitor)
Antibody therapeutic designed to inhibit MASP-3 to block activation of the alternative complement pathway; in clinical development for paroxysmal nocturnal hemoglobinuria and other alternative-pathway disorders.
PDE7 small-molecule inhibitor for addiction disorders
Oral small-molecule phosphodiesterase 7 inhibitor developed to modulate dopamine pathways implicated in substance use disorders and reduce craving and relapse behaviors; progressed through Phase 1 clinical trials.
PPARγ small-molecule modulators for addiction
Small-molecule PPARγ agonists explored for reduction of craving and modulation of anxiety in substance use disorders; supported by investigator-led and NIH-funded clinical studies.
Targeted Complement Activation Therapeutics (T-CAT platform)
Engineered fusion-protein platform combining complement pathway effectors with antigen-targeting domains to direct complement-mediated killing of pathogens, including multidrug-resistant organisms.
Services
Processes to evaluate and respond to physician requests for early access to investigational therapeutics, including safety reporting and adherence to applicable laws and contractual conditions.
Planning and conduct of early- and late-stage clinical trials including adaptive platform participation, safety/tolerability assessments, and trial data analysis.
Collaborative research agreements with academic centers to advance mechanistic studies and translate complement and inflammation science into therapeutic programs.
Processes to evaluate and respond to physician requests for early access to investigational therapeutics, including safety reporting and adherence to applicable laws and contractual conditions.
Planning and conduct of early- and late-stage clinical trials including adaptive platform participation, safety/tolerability assessments, and trial data analysis.
Collaborative research agreements with academic centers to advance mechanistic studies and translate complement and inflammation science into therapeutic programs.
Expertise Areas
- GPCR drug discovery and deorphanization
- Monoclonal antibody and biologics development
- Small-molecule therapeutic discovery
- Complement-system therapeutics
Key Technologies
- GPCR deorphanization
- Cellular redistribution assay (CRA)
- High-throughput screening (HTS)
- Monoclonal antibody engineering